Gerald Tarirah, MD
Pulmonary Disease · Macon, GANPI 1851313431
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,800 of the $29,117 with a category attached, or 64.6%. AstraZeneca accounts for 78.2% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2020 at $13,134 and has fallen 85.1% since, to $1,958 in 2025. Among pulmonary disease clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 384 payments — averaging $75.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$23K
- GSK$2K
- ANI Pharmaceuticals, Inc.$729
- Mallinckrodt Hospital Products Inc.$477
- Mylan Specialty L.p.$445
- Regeneron Healthcare Solutions, Inc.$445
- plus $2K from 25 others
Across 8 payments — averaging $1141.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$7K
- AstraZeneca$2K
What the payments were for
- Speaking & faculty fees$18,80065%
- Travel & lodging$2,2998%
- Food & beverage$7,65826%
- Education$3591%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 93 | $22,779 |
| GSK | 98 | $1,971 |
| ANI Pharmaceuticals, Inc. | 46 | $729 |
| Mallinckrodt Hospital Products Inc. | 10 | $477 |
| Mylan Specialty L.p. | 22 | $445 |
| Regeneron Healthcare Solutions, Inc. | 21 | $445 |
| Boehringer Ingelheim | 15 | $288 |
| Grifols USA, LLC | 8 | $256 |
| Johnson & Johnson | 10 | $249 |
| Novo Nordisk | 2 | $238 |
| Insmed, Inc. | 12 | $222 |
| Baxter Healthcare | 8 | $149 |
| Sanofi | 6 | $145 |
| Verona Pharma, Inc. | 3 | $93 |
| Advanced Respiratory, Inc | 4 | $91 |
| Actelion Pharmaceuticals US, Inc. | 4 | $82 |
| Ambu Inc. | 2 | $62 |
| Body Vision Medical Inc. | 1 | $56 |
| Merck | 3 | $44 |
| Viatris Specialty LLC | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Sunovion Pharmaceuticals Inc. | 2 | $34 |
| Electromed, Inc. | 2 | $29 |
| Tempus AI, Inc | 1 | $23 |
| Inogen, Inc. | 1 | $23 |
| Circassia Inc. | 1 | $20 |
| Haemonetics Corporation | 1 | $19 |
| Pulmonx Corporation | 1 | $18 |
| Bayer | 1 | $18 |
| Philips North America LLC | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$21,320
- ACTHAR$144
- Wegovy$125
- Prolastin-C$124
- NUCALA$124
- XARELTO$124
- PURIFIED CORTROPHIN GEL$123
How this compares
$29,117 in reported general payments places this provider in the 90th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 679 | $881,118 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 349 | $397,967 |
| SymbicortBudesonide/Formoterol Fumarate | 212 | $86,696 |
| Spiriva RespimatTiotropium Bromide | 91 | $80,199 |
| EliquisApixaban | 53 | $42,707 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 44 | $31,170 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 29 | $23,866 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $13,730 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 56 | $12,474 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 262 | $11,120 |
| Roflumilast | 70 | $8,603 |
| Montelukast Sodium | 467 | $3,563 |
| BreynaBudesonide/Formoterol Fumarate | 13 | $3,174 |
| Fluticasone Propionate | 198 | $2,702 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $2,319 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $1,971 | $926,017750 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $22,779 | $484,664561 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $288 | $104,065120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Macon
- Charles CallenderMacon$20K
- John KingMacon$19K
- Lawrence McDermottSavannah$963K
- Vivek SambharaGainesville$417K
- Chad MillerAustell$382K
- Nehal BhattAthens$371K
- Maria MascoloRincon$358K
- Colin SwensonAtlanta$255K
- David MillerDecatur$206K
- Michael MullinsSavannah$132K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.